DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/bz66rb/cognitive) has announced the addition of the "Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2014" report to their offering.
This report provides comprehensive information on the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS) and special features on late-stage and discontinued projects.
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Companies Mentioned:
- Eli Lilly and Company
- Merck & Co., Inc.
- Takeda Pharmaceutical Company Limited
- Avineuro Pharmaceuticals, Inc.
- Novartis AG
- FORUM Pharmaceuticals Inc.
- H. Lundbeck A/S
- Pfizer Inc.
- Suven Life Sciences Ltd.
- Mithridion, Inc.
- CoMentis, Inc.
- Upsher-Smith Laboratories, Inc.
- Siena Biotech S.p.A.
- Dart NeuroScience LLC
- Intra-Cellular Therapies, Inc.
- Amarantus Bioscience Holdings, Inc.
- Mnemosyne Pharmaceuticals, Inc.
- SK Biopharmaceuticals Co., Ltd.
- AbbVie Inc.
- Saniona AB
For more information visit http://www.researchandmarkets.com/research/bz66rb/cognitive
